Tauopathies Treatment Market Analysis | Coherent Market Insights

1
Coherent Market InsightS

• Market Research and Business Consulting
  Services
• https//www.coherentmarketinsights.com/
• COVID-19 Impact Tracker

2
Tauopathies Treatment Market Analysis
(2020-2027)

• Tauopathies is the class of more than 20
  neurodegenerative conditions, characterized by
  tau protein aggregation in the brain.
• Currently, only a limited number of therapeutics
  are commercialized for treatment of tauopathies.
  The increasing number of patients affected by
  conditions such as progressive supranuclear palsy
  (PSP) and frontotemporal lobar degeneration
  (FTLD-TAU) corticobasal degeneration is expected
  to facilitate market growth to a great extent.
  PSP is a 4-repeat (4R) tauopathy, composed of a
  preponderance of four-repeat tau isoforms and a
  characteristic biochemical profile.

3

• According to the BioMed Central (BMC) journal,
  Alzheimers disease (AD) is the most prominent
  tauopathy which is a common cause of dementia in
  the elderly. AD is a progressive, incurable,
  degenerative disease of the brain that is
  characterized by the presence of ß- amyloid (Aß)
  and tau pathology. Currently, there are no
  disease-modifying drugs available for Alzheimers
  and only symptomatic treatments trying to offset
  the neurotransmitter disturbance exist. In the
  last 15 years, no significant novel drug for
  Alzheimers has been approved, despite extensive
  clinical trials. The drug pipeline has been
  inundated with more than 400 failed clinical
  trials since the last symptomatic AD drug was
  approved.
• Factors such as the ongoing research
  development activities to develop novel drugs as
  well as the increasing prevalence of dementia are
  expected to boost the growth of the global
  tauopathies treatment market during the forecast
  period. For instance, according to the World
  Health Organization (WHO), around 50 million
  people across the globe had dementia in 2019 and
  about 10 million novel cases are diagnosed each
  year.

4
Global Tauopathies Treatment Market - Impact of
Coronavirus (Covid-19) Pandemic

• The tauopathies treatment market growth has been
  affected significantly due to the outbreak of
  COVID-19 all over the world. It is challenging
  for researchers and key industry players to
  obtain funding for performing clinical trials and
  discovering and developing a vaccine for
  COVID-19.  However, researchers are under the
  process to understand how this deadly virus
  affects people with Alzheimers and other
  neurodegenerative diseases.
• The all-inclusive version of the report will
  include the impact of COVID-19 and the probable
  changes in the future outlook of the industry by
  taking into account technological, social,
  political, and economical parameters.

5
s

• The global tauopathies treatment market is
  estimated to be valued at US 712.7 million in
  2020 and is expected to grow at a CAGR of
  10.07 during the forecast period (2020-2027).

6
Figure 1 Global Tauopathies Treatment Market
Share () Analysis, By Distribution Channel, 2020
7
Novel drugs treatment are expected to boost the
growth of the global tauopathies treatment market

•  The approvals of clinical trials are expected to
  pr opel the market growth and create lucrative
  growth opportunities for the market players
  during the forecast period.
• For instance, in November 2017, Cortice
  Biosciences presented results from a
  placebo-controlled phase I double-blinded
  clinical trial assessing TPI 287. TPI 287 is a
  brain penetrable novel microtubule-stabilizing
  agent for the treatment of corticobasal syndrome
  (CBS), progressive supranuclear palsy (PSP), and
  Alzheimers disease.  All three of these
  indications are known as tauopathies which have
  no disease-modifying therapies and are associated
  with constant neurodegeneration and eventually
  result in patients death.

8

• Furthermore, this disease being a capital
  intensive and risky investment, companies are
  collaborating to synergize their respective
  strengths and collaboratively capitalize the
  opportunity. For instance, in July 2019,
  REGENXBIO Inc. and Neurimmune AG entered a
  development and commercialization license
  agreement to determine and co-develop novel AAV
  gene therapies by making use of NAV Vectors. The
  companies aim to deliver human antibodies
  alongside targets concerned with chronic
  neurodegenerative diseases which also include
  tauopathies.
• Besides, in February 2020, Oligomerix, Inc.
  presented efficacy data in two pre-clinical
  models of tauopathy. The findings were presented
  by the company at the TAU2020 Global Conference.
  According to Oligomerixs findings, their lead
  compound decreased soluble levels of tau
  self-association and caused a dose-dependent drop
  of insoluble as well as phosphorylated insoluble
  tau aggregates in the tau mice brains, which
  represents tauopathy in Alzheimers disease (AD).

9
Global Tauopathies Treatment Market - Restraints

• However, limited availability of approved drugs
  for tauopathies is a major factor which is
  expected to hamper the growth of the global
  tauopathies treatment market. Delay in diagnosis
  and deficient understanding of the cellular
  mechanisms implicated in pathogenic tau-induced
  dysfunction and neuronal death are expected to
  majorly restrict the market growth.

10
(No Transcript)
11
Global Tauopathies Treatment Market Regional
Analysis

• North America accounted for the largest share in
  the tauopathies treatment market in 2019 and is
  expected to retain its dominance throughout the
  forecast period. This is mainly attributed to the
  fact that therapy prices in this region is
  signficiantly higher than other economies.  
• Moreover, in January 2020, Pfizers asset of
  Parkinsons and Alzheimers was acquired by
  Biogen for US 710 million. The companys aim
  behind this acquisition is to develop
  CNS-penetrate inhibitor of CK1 for patients with
  neurological and behavioral neurological symptoms
  in various neurological and psychiatric diseases.

12

• Furthermore, the market in Europe is expected to
  account for the second-largest market share owing
  to investments by governments and pharmaceutical
  companies for development of tauopathies
  treatment. For instance, in January 2019,
  Aquinnah Pharmaceuticals received a grant of US
  750,000 from the Tau Consortium and the
  Alzheimers Association to advance novel
  therapies for tauopathy diseases. Aquinnah, with
  this funding, has developed models of neurons
  that replicate the human tau stress granule
  pathology. The company is also involved in
  identifying molecules having the potential to be
  developed as new drugs.

13
Figure 2 Global Tauopathies Treatment Market
Value (US Mn) Y-o-Y Growth (), 2017-2027
14
Global Tauopathies Treatment Market - Competitive
Landscape

• Key players operating in the global tauopathies
  treatment market are Avanir Pharmaceuticals,
  Inc., Otsuka Pharmaceutical Co., Ltd., AB
  Science, Cortice Biosciences, REGENXBIO Inc.,
  Aquinnah Pharmaceuticals, Neurimmune, Oligomerix,
  Inc., Biogen, TauRx, Sellas, Catalent Inc.,
  Selvita S.A, Bristol-Myers Squibb Company,
  Chronos Therapeutics Limited, and SK
  Biopharmaceuticals Co., Ltd.

15

• Request sample copy here
• Request PDF brochure here
• Request Customization here
• Talk to Analyst
• Buy Now
• Reference
• https//www.coherentmarketinsights.com/market-insi
  ght/tauopathies-treatment-market-3995

16
About Us

• Coherent Market Insights is a global market
  intelligence and consulting organization focused
  on assisting our plethora of clients achieve
  transformational growth by helping them make
  critical business decisions.
• What we provide
• Customized Market Research Services
• Industry Analysis Services
• Business Consulting Services
• Market Intelligence Services
• Long term Engagement Model
• Country Specific Analysis

17
Contact Us   

• Mr. Shah
• Coherent Market Insights Pvt. Ltd.
• Address 1001 4th ave, 3200 Seattle, WA 98154,
  U.S.
• Phone [phone]
• Email sales_at_coherentmarketinsights.com

18
Thank You!

• Kindly follow CMI Social Media Profiles for the
  latest company updates
• Facebook
• Linkedin
• Twitter
• https//www.coherentmarketinsights.com/